The Xact Kapitalforvaltning AB Acquires 1,000 Shares of DexCom, Inc. (DXCM)

The Xact Kapitalforvaltning AB Acquires 1,000 Shares of DexCom, Inc. (DXCM)

Other hedge funds and other institutional investors have also bought and sold shares of the company. Livforsakringsbolaget Skandia Omsesidigt acquired a new position in DexCom during the first quarter valued at $136,000. IFP Advisors Inc raised its position in DexCom by 9.3% in the first quarter. IFP Advisors Inc now owns 1,863 shares of the medical device company’s stock valued at $158,000 after buying an additional 159 shares in the last quarter. Mn Services Vermogensbeheer B.V. raised its position in DexCom by 3.8% in the first quarter. Mn Services Vermogensbeheer B.V. now owns 2,254 shares of the medical device company’s stock valued at $179,000 after buying an additional 83 shares in the last quarter. Daiwa Securities Group Inc. raised its position in DexCom by 475.0% in the first quarter. Daiwa Securities Group Inc. now owns 2,300 shares of the medical device company’s stock valued at $195,000 after buying an additional 1,900 shares in the last quarter. Finally, Accredited Investors Inc. purchased a new stake in DexCom during the third quarter valued at about $207,000.

Xact Kapitalforvaltning AB raised its stake in DexCom, Inc. (NASDAQ:DXCM) by 10.3% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 10,704 shares of the medical device company’s stock after buying an additional 1,000 shares during the period. Xact Kapitalforvaltning AB’s holdings in DexCom were worth $907,000 as of its most recent SEC filing.

DexCom, Inc. (NASDAQ:DXCM) opened at 67.68 on Monday. The firm’s market cap is $5.85 billion. DexCom, Inc. has a 12 month low of $57.68 and a 12 month high of $96.38. The firm’s 50-day moving average price is $72.24 and its 200-day moving average price is $73.86.

DXCM has been the topic of several recent research reports. Cowen and Company reissued an “outperform” rating and issued a $90.00 price target on shares of DexCom in a research note on Tuesday, April 18th. BTIG Research downgraded DexCom from a “buy” rating to a “neutral” rating in a research note on Wednesday, May 3rd. William Blair reissued an “outperform” rating on shares of DexCom in a research note on Thursday, April 27th. Oppenheimer Holdings Inc. set a $98.00 price target on DexCom and gave the company a “buy” rating in a research note on Wednesday, May 3rd. Finally, Canaccord Genuity dropped their price target on DexCom from $95.00 to $90.00 and set a “buy” rating on the stock in a research note on Wednesday, May 3rd. Four analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. DexCom currently has an average rating of “Buy” and a consensus target price of $90.44. In other news, EVP Richard Doubleday sold 3,182 shares of the firm’s stock in a transaction that occurred on Tuesday, May 23rd. The shares were sold at an average price of $68.29, for a total transaction of $217,298.78. Following the completion of the sale, the executive vice president now owns 72,395 shares in the company, valued at approximately $4,943,854.55. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Jacob Steven Leach sold 21,317 shares of the firm’s stock in a transaction that occurred on Tuesday, March 14th. The stock was sold at an average price of $77.63, for a total transaction of $1,654,838.71. The disclosure for this sale can be found here. In the last quarter, insiders sold 100,312 shares of company stock valued at $7,578,606. Company insiders own 2.80% of the company’s stock.

DexCom Company Profile Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:DXCM”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Receive News & Ratings for DexCom Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for DexCom Inc. and related companies with our FREE daily email newsletter.

Related posts

Leave a Comment